Details for New Drug Application (NDA): 017561
✉ Email this page to a colleague
NDA 017561 describes CELESTONE, which is a drug marketed by Schering, Merck Sharp Dohme, and Organon, and is included in five NDAs. Additional details are available on the CELESTONE profile page.
The generic ingredient in CELESTONE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
The generic ingredient in CELESTONE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
Summary for 017561
| Tradename: | CELESTONE |
| Applicant: | Schering |
| Ingredient: | betamethasone sodium phosphate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
